Gibson C Michael, Cannon Christopher P, Murphy Sabina A, Marble Susan J, Barron Hal V, Braunwald Eugene
TIMI Study Group, Department of Medicine, Brigham and Women's Hospital, Boston, Mass 02215, USA.
Circulation. 2002 Apr 23;105(16):1909-13. doi: 10.1161/01.cir.0000014683.52177.b5.
Although 90-minute TIMI flow grades (TFGs), corrected TIMI frame counts (CTFCs), and TIMI myocardial perfusion grades (TMPGs) have been associated with 30-day outcomes, we hypothesized that these indices would be related to long-term outcomes after thrombolytic administration.
As a substudy of the TIMI 10B trial (tissue plasminogen activator versus tenecteplase), 49 centers carried out 2-year follow-up. TIMI grade 2/3 flow (Cox hazard ratio [HR] 0.41, P=0.001), reduced CTFCs (faster flow, P=0.02), and an open microvasculature (TMPG 2/3) (HR 0.51, P=0.038) were all associated with improved 2-year survival. Rescue percutaneous coronary intervention (PCI) of closed arteries (TFG 0/1) at 90 minutes was associated with reduced mortality (P=0.03), and mortality trended lower with adjunctive PCI of open (TFG 2/3) arteries (P=0.11). In a multivariate model correcting for previously identified correlates of mortality (age, sex, pulse, left anterior descending coronary artery infarction, and any PCI during initial hospitalization), patency (TFG 2/3) (HR 0.32, P<0.001), CTFC (P=0.01), and TMPG 2/3 remained associated with reduced mortality (HR 0.46, P=0.02).
Both improved epicardial flow (TFG 2/3 and low CTFCs) and tissue-level perfusion (TMPG 2/3) at 90 minutes after thrombolytic administration are independently associated with improved 2-year survival, suggesting complementary mechanisms of improved long-term survival. Although rescue PCI reduced long-term mortality, improved microvascular perfusion (TMPG 2/3) before PCI was also related to improved mortality independently of epicardial blood flow and the performance of rescue or adjunctive PCI. Further prospective trials are warranted to re-examine the benefit of early PCI with thrombolysis.
尽管90分钟的心肌梗死溶栓治疗(TIMI)血流分级(TFG)、校正的TIMI帧计数(CTFC)和TIMI心肌灌注分级(TMPG)与30天预后相关,但我们推测这些指标与溶栓治疗后的长期预后有关。
作为TIMI 10B试验(组织型纤溶酶原激活剂与替奈普酶对比)的一项子研究,49个中心进行了为期2年的随访。TIMI 2/3级血流(Cox风险比[HR] 0.41,P = 0.001)、较低的CTFC(血流更快,P = 0.02)以及开放的微血管(TMPG 2/3)(HR 0.51,P = 0.038)均与2年生存率提高相关。90分钟时对闭塞动脉(TFG 0/1)进行补救性经皮冠状动脉介入治疗(PCI)与死亡率降低相关(P = 0.03),对开放动脉(TFG 2/3)进行辅助性PCI时死亡率有降低趋势(P = 0.11)。在一个校正了先前确定的死亡率相关因素(年龄、性别、脉搏、左前降支冠状动脉梗死以及初次住院期间的任何PCI)的多变量模型中,血管通畅(TFG 2/3)(HR 0.32,P < 0.001)、CTFC(P = 0.01)和TMPG 2/3仍与死亡率降低相关(HR 0.46,P = 0.02)。
溶栓治疗后90分钟时改善的心外膜血流(TFG 2/3和低CTFC)和组织水平灌注(TMPG 2/3)均与2年生存率提高独立相关,提示改善长期生存的互补机制。尽管补救性PCI降低了长期死亡率,但PCI前改善的微血管灌注(TMPG 2/3)也与死亡率改善相关,且独立于心外膜血流以及补救性或辅助性PCI的实施情况。有必要进行进一步的前瞻性试验以重新审视早期PCI联合溶栓治疗的益处。